Extended release formulation of levetiracetam

US7858122B2 · kind B2 · utility

Assignee

• UCB PHARMA S.A. · BE

Inventors

• Rajesh Kshirsagar · Vadodara, IN
• Mayank Joshi · Weston, US
• Yogesh Raichandani · Vadodara, IN

Key dates

• Filing date: Aug 31, 2005
• Grant date: Dec 28, 2010
• Expiry date: Sep 17, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/2077
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patients blood plasma, which comprises administering orally to a patient in need thereof, an extended release tablet that provides a peak blood plasma level of Levetiracetam in from about eight to about Sixteen hours. The core is prepared by Wet granulation, Dry granulation or Direct compression and optionally the tablet core is coated either in an coating pan or in and Fluidized bed system.